Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Geron Corp

NASDAQ: GERN · Life Sciences · 3 alerts · CIK 886744

Share price
$0.9419Close, Nov 16
Market cap
$607M
Shares outstanding
644.24MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Geron Corp filings on SEC EDGAR ↗

4:48 PM ET 8-K
Clinical Trial Data

Geron Clinical Trial Data

Geron Corporation is discontinuing its Phase 3 IMpactMF clinical trial of imetelstat in relapsed/refractory myelofibrosis based on a recommendation from an independent Data Monitoring Committee. The committee advised that the trial was unlikely to meet its primary endpoint of overall survival, although no new safety signals were observed.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.